The Company is providing the following full-year 2022 financial guidance for RemainCo Zimmer Biomet – this guidance does not include any projected financial results from the businesses that are part of the planned spinoff of ZimVie from the Company. For comparison purposes only, unaudited 2021 net sales for RemainCo Zimmer Biomet are estimated to be $6.827 billion, based on total Company net sales of $7.836 billion less the Dental & Spine product category net sales of $1.009 billion.
Zimmer Biomet Holdings…today announced one-year data from a multicenter, prospective, randomized controlled trial to evaluate the impact of mymobility with Apple Watch, a first-of-its-kind remote care management platform. The data show that using mymobility with Apple Watch following primary knee arthroplasty, commonly known as knee replacement, can effectively guide rehabilitation, demonstrate similar outcomes to traditional care models, and significantly reduce the number of outpatient physical therapy (PT) visits.
In addition, use of mymobility with Apple Watch was associated with significantly fewer surgery-related emergency department (ED) visits, which could translate to lower costs of care. The data will be presented at a podium session at the 2022 annual meeting of the American Association of Hip and Knee Surgeons (AAHKS).